Drug intelligence / Profile preview

Luminespib

Development stage: Phase 2
Lead developer: Novartis
Modality: Small Molecules
Administration: Intravenous

Overview

Luminespib is a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. It binds with high affinity to Hsp90, leading to the proteasomal degradation of oncogenic client proteins, inhibition of cell proliferation, and elevation of heat shock protein 72 (Hsp72) in various human tumor cell lines. Developed through a collaboration between The Institute of Cancer Research and Vernalis, it was licensed to Novartis.

Other names: luminespibNVP-AUY922NVP-AUY-922NVP-AUY 922VER-52296VER52296VER 52296AUY-922AUY922AUY 922

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)HSP90B1 (GRP94)TRAP1 (Tumor necrosis factor receptor-associated protein 1)HSP90AB1 (Heat shock protein HSP 90-beta)

Beyond the preview

Go deeper on Luminespib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luminespib.

Explore the full profile